A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3 Meeting Abstract
| Authors: | Estey, E. H.; Fisher, T.; Giles, F.; Feldman, E. J.; Ehninger, G.; Schiller, G. J.; Klimek, V. M.; Nimer, S. D.; De Angelo, D. J.; Gilliland, D. G.; Fox, E.; Wang, Y. F.; Rosamilia, M.; Resta, D.; Cohen, P.; Stone, R. M. |
| Abstract Title: | A randomized phase II trial of the tyrosine kinase inhibitor PKC412 in patients (pts) with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS) characterized by wild-type (WT) or mutated FLT3 |
| Meeting Title: | 45th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 102 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2003 Dec 6-9 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2003-11-01 |
| Start Page: | 614A |
| End Page: | 615A |
| Language: | English |
| ACCESSION: | WOS:000186536702268 |
| PROVIDER: | wos |
| PUBMED: | 14650391 |
| Notes: | Meeting Abstract: 2270 -- 45th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2003 -- SAN DIEGO, CALIFORNIA -- 1 -- Source: Wos |
